期刊文献+

Occult Hepatitis B Reactivation after Liver Transplant: The Role of a Novel Mutation in the Surface Antigen

原文传递
导出
摘要 Occult hepatitis B infection is characterized by loss of hepa-titis B surface antigen(HBsAg)and persistence of low levels of hepatitis B virus(HBV)replication that may or may not be detectable in plasma/serum.We present a case of HBV reactivation in a male patient who underwent orthotopic liver transplant for hepatocellular carcinoma secondary to active hepatitis C(HCV)infection.Pre-transplant,he was HBsAg-negative and hepatitis B core antibody-positive,with an undetectable HBV viral load that was incidentally found to be positive at a very low HBV viral load on the day of transplant.Post-transplant,his HBsAg remained undetect-able,with an undetectable HBV viral load,until eradication of his HCV infection with direct acting antiviral agents.Af-ter eradication of HCV,there was reactivation of HBV,with a high viral load and emergence of serum HBsAg.A deep sequencing genetic analysis of his HBV both pre-and post-transplant revealed the presence of a mutation in the"a"determinant of the HBV surface antigen.The role of HBV genotype'a'determinant mutation in HBV reactivation post-transplant is unknown and needs further examination.Our experience suggests a possible role for antiviral prophylaxis in these patients or monitoring of HBV viral loads post-transplant.
出处 《Journal of Clinical and Translational Hepatology》 SCIE 2021年第1期136-138,共3页 临床与转化肝病杂志(英文版)
  • 相关文献

参考文献4

二级参考文献179

  • 1Dienstag J L, Schiff E R, Wright T L, et al. 1999. Lamivudine as initial treatment for chronic hepatitis b in the united states. N Engl J Med, 341(17): 1256-1263.
  • 2Ferreira R, Carvalheiro J, Tortes J, et al. 2012. Fatal hepatitis b reactivation treated with entecavir in an isolated anti-hbs positive lymphoma patient: A case report and literature review. Saudi J Gastroenterol, 18(4): 277-281.
  • 3Fukushima N, Mizuta T, Tanaka M, et al. 2009. Retrospective and prospective studies of hepatitis b virus reactivation in malignant lymphoma with occult hbv carrier. Ann Oneol, 20(12): 2013-2017.
  • 4Kim I K, Kim B G, Kim W, et al. 2012. Clinical prediction of failure of lamivudine prophylaxis for patients with hepatitis b infection undergoing cytotoxic chemotherapy for malignancy. Antimicrob Agents Chemother. 56(11): 5511-5519.
  • 5Kondili L A, Osman H, Mutimer D. 2004. The use of lamivudine for patients with acute hepatitis b (a series of cases). J Viral Hepat, 11 (5): 427-431.
  • 6Lai C L, Chien R N, Leung N W, et al. 1998. A one-year trial of [amivudine for chronic hepatitis b. Asia hepatitis lamivudine study group. N Engl J Med, 339(2): 618.
  • 7Lee I C, Huang Y H, Chu C J, et al. 2010. Hepatitis b virus reactivation after 23 months of rituximab-based chemotherapy in an hbsag-negative, anti-hbs-positive patient with follicular lymphoma. J Chin Med Assoc, 73(3): 156-160.
  • 8Lu M,Lorentz T. 2003. De novo infection in a renal transplant recipient caused by novel mutants of hepatitis b virus despite the presence of protective anti-hepatitis b surface antibody. J Infect Dis 187(8): 1323-1326.
  • 9Matsue K, Kimura S, Takanashi Y, et al. 2010. Reactivation of hepatitis b virus after rituximab-containing treatment in patientswith cd20-positive b-cell lymphoma. Cancer, 116(20): 4769-4776.
  • 10Miyake Y, Iwasaki Y, Takaki A, et al. 2008. Lamivudine treatment improves the prognosis of fulminant hepatitis b. Intern Med, 47(14): 1293-1299.

共引文献58

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部